Leila Mouelhi
Haïfa Mekki
Radhouane Debbeche
Mohamed Salem
Taoufik Najjar


Background : Thromboembolic manifestations are frequent in patients with inflammatory bowel disease.
Aims: To explaim the mechanisms of thromboembolic manifestations in inflammatory bowel disease.
Methods: Literature review.
Results: Risk factors of thrombosis in inflammatory bowel disease are acquired or genetic. The most important factors are thrombocytosis, increased of activation of platelets and hyperhomocysteinemia. Other factors such factor V leiden, antithrombin III and antiphospholipid antibodies are observed in inflammatory bowel disease patients but not always correlated with thromboembolic manifestations.
Conclusion: The mechanisms of thrombosis in inflammatory bowel disease are complex are intricate.


Thrombosis, Inflammatory bowel disease



  1. Irving PM, Pasi KJ, Rampton DS. Thrombosis in inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3:617-628.
  2. Bernstein CN, Blanchard JF, Houston DS et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-434.
  3. Miehsler W, Reinisch W, Valic E et al. Is inflammatory bowel disease an independant and disease specific risk factor for thromboembolism ? Gut 2004;53:542-548.
  4. Solem CA, Loftus EV Jr, Tremaine WJ et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101.
  5. Talbot RW, Heppell J, Dozois RR et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-145.
  6. Torkvist I, Thorlacius H, Sjoqvist U et al. Low molecul weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999;13:1325-1328.
  7. Hatoum OA, Spinelli KS, Abu-Hajir M et al. Mesenteric venous thrombosis in inflammatory bowel disease. J Clin Gastroenterol 2005;39:27-31.
  8. Novacek G, Haumer M, Schima W et al. Aortic mural thrombi in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:430-435.
  9. Magro F, Dinis-Ribeiro M, Araujo FM et al. High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003;15:1157-1163.
  10. Collins CE, Rampton DS. Platelets in inflammatory bowel disease - pathogenic role and therapeutic implications. Aliment Pharmacol Ther 1997;11:237-247.
  11. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-1219.
  12. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993;34:247-251.
  13. Collins CE, Cahill MR, Newland AC et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106:840-845.
  14. Danese S, Katz JA, Saibeni S et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-1441.
  15. Andre P, Nannizzi-Alaino I, Prased SK, Philips DR. Platelets derived CD40L: The switch hitting player of cardiovascular disease. Circulation 2002;106:896-899.
  16. Andre P, Prased KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002;8:247-252.
  17. Irving PM, Macey MG, Webb L et al. Formation of platelet leucocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004;10:361-372.
  18. Boehme M, Autschbach F, Zuna I et al. Elevated serum levels and reduced immunohistochemical expression of thrombomodulin in active ulcerative colitis. Gastroenterology 1997;113:107-117.
  19. Faioni EM, Ferrero S, Fontana G et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004;32:S266-S270.
  20. Stevens TR, James JP, Simmonds NJ et al. Circulating von Willebrad factor in inflammatory bowel disease. Gut 1992;33:502-506.
  21. Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis 2002;13:105-116
  22. Stevens TR, Harley SL, Groom JS et al. Anti-endothelial cell antibodies in inflammatory bowel disease. Dig Dis Sci 1993;38:426- 432.
  23. Boushey CJ, Beresford SAA, Omen GS et al. A quantitative assessment of plasma homocysteine as a risk for vascular disease. JAMA 1995;274:1049-1057.
  24. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-1781.
  25. Saibeni S, Cattaeno M, Vecchi M et al. Low vitamin B6 plasma levels,a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003;98:112-117.
  26. Haagsma CJ, Blom HJ, van Riel PLCM et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
  27. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
  28. Cattaeno M, Vecchi M, Zighetti ML et al. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998;80:542-545.
  29. Vasilopoulos S, Saiean K, Emmons J et al. Terminal ileum resection is associated with higher plasma homocysteine levels in Crohn's disease. J Clin Gastroenterol 2001;33:132-136.
  30. Stabler SP, Allen RH, Savage DG et al. Clinical diagnosis and spectrum of cobalamin deficiency. Blood 1990;76:871-881.
  31. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996;87:3531-3544.
  32. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
  33. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V leiden (activated protein C resistance). Blood 1995;86:4700-4702.
  34. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A. Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003;98:1247-1251.
  35. Huisman MV, Rosendaal F. Thrombophilia. Curr Opin Hematol 1999;6:291-297.
  36. Koenigs K, Phedran P, Spiro H. Thrombosis in inflammatory bowel disease. J Clin Gastroenterol 1987;9:627-631.
  37. Lake AM, Stauffer JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease, response to therapy. Am J Dig Dis 1978;23:897-902.
  38. Sonto JC, Martinez E, Roca M et al. Prothrombic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995;40:1883-1889.
  39. Saibeni S, Vecchi M, Valsecchi C, Faioni EM, Razzari C, de Franchis R. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig Dis Sci 2001;46:637-643.
  40. Vaezi MF, Rustagi PK, Elson CO. Transient protein S deficiency associated with cerebral venous thrombosis in active ulcerative colitis. Am J Gastroenterol 1995;90:313-315.
  41. Saibeni S, Ciscato C, Vecchi M et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006;4:1510-1516.
  42. Chamouard P, Grunebaum L, Weisel ML et al. Prevalence and significance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci 1994;39:1501-1504.
  43. Koutroubakis IE, Petritsch E, Anagnostopoulos E et al. Anticardiolipin,and anti-beta-2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998;43:2507-2512.
  44. Aichbichler BW, Petritsch W, Reicht GA et al. Anticardiolipin antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1999;44:852-856.